Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
LOW MOLECULAR WEIGHT HEPARIN (LMWH)
Haematology · Haematology · Level 1
|
HIRUDIN
Haematology · Haematology
|
|---|---|---|
| Mechanism of action | Activates antithrombin but due to shorter length preferentially inhibits factor Xa |
is via direct irreversible binding to thrombin Causes a prolongation of bleeding time |
| Absorption | up to 90% via SC (greater than heparin) |
administered SC |
| Protein binding | less prot bind than heparin |
— |
| Volume of distribution | Vd ~ 0.1L/kg |
— |
| Metabolism | Hepatic depolymerisation and desulfation to less active fragments |
— |
| Excretion | urine as 40% of dose and 10% active fragments, dose adjustment in renal failure |
excreted in the urine, dose adjustment |
| Half-life | 2-4 times longer half-life than heparin |
— |
| Adverse Effects Toxicity | Bleeding |
Bleeding |
| Class Group | Anticoagulants |
Anticoagulants |
| Indications Uses | 1. the prevention of venous thromboembolic disease |
— |
| Introduction | Enoxaparin is a LMWH prepared from |
Is a naturally occurring peptide found in leaches saliva with anticoagulant properties |
| Legacy Cicm Level | Level 1 |
Not in list |
| Presentation | Usually s/c, but can be given i.v. Monitor: |
— |
| Special Points | Reversal: |
Reversal: |